Literature DB >> 15013230

Drug, enzyme and peptide delivery using erythrocytes as carriers.

Carmen Gutiérrez Millán1, María Luisa Sayalero Marinero, Aránzazu Zarzuelo Castañeda, José M Lanao.   

Abstract

Erythrocytes are potential biocompatible vectors for different bioactive substances, including drugs. These can be used successfully as biological carriers of drugs, enzymes and peptides. There are currently diverse methods that permit drug encapsulation in erythrocytes with an appropriate yield. The methods most commonly employed are based on a high-haematocrit dialysis procedure, mainly hypo-osmotic dialysis. Erythrocytes loaded with drugs and other substances allow for different release rates to be obtained. Encapsulation in erythrocytes significantly changes the pharmacokinetic properties of drugs in both animals and humans, enhancing liver and spleen uptake and targeting the reticulo-endothelial system (RES). Amongst other applications, erythrocytes have been used for drug-targeting the RES with aminoglycoside antibiotics; the selective transport to certain organs and tissues of certain antineoplastic drugs, such as methotrexate, doxorubicine, etoposide, carboplatin, etc.; the encapsulation of angiotensin-converting enzyme (ACE) inhibitors, systemic corticosteroids, the encapsulation of new prodrugs with increased duration of action, etc. Erythrocytes are also attractive systems in the sense of their potential ability to deliver proteins and therapeutic peptides. Thus, erythrocytes have been used for the transport of enzymes destined for the correction of metabolic alterations as l-asparaginase, alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (AlDH) among others. Erythrocytes have been used successfully as carriers of anti-HIV peptides, such as AZT, nucleoside analogues, antisense oligonucleotides, antineoplastic peptides, erythropoietin, interleukin 3, etc. Amongst other applications, mention may be made of paramagnetic erythrocytes, encapsulation of MRI contrast agents or the study of the metabolism of the red cell. Although erythrocytes have been applied with different uses in human medicine, their deployment is still very limited due to difficulties involving storage, its exposure to contamination and the absence of a validated industrial procedure for its preparation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013230     DOI: 10.1016/j.jconrel.2003.11.018

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  33 in total

1.  Cell permeable cocaine esterases constructed by chemical conjugation and genetic recombination.

Authors:  Tien-Yi Lee; Yoon Shin Park; George A Garcia; Roger K Sunahara; James H Woods; Victor C Yang
Journal:  Mol Pharm       Date:  2012-03-28       Impact factor: 4.939

2.  Engineering erythrocytes as a novel carrier for the targeted delivery of the anticancer drug paclitaxel.

Authors:  Gamaleldin I Harisa; Mohamed F Ibrahim; Fars Alanazi; Gamal A Shazly
Journal:  Saudi Pharm J       Date:  2013-01-07       Impact factor: 4.330

Review 3.  Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia.

Authors:  Xavier Thomas; Caroline Le Jeune
Journal:  Int J Hematol Oncol       Date:  2016-05-05

4.  Converting Red Blood Cells to Efficient Microreactors for Blood Detoxification.

Authors:  Can Xu; Xiangyu Yang; Xiao Fu; Rui Tian; Orit Jacobson; Zhantong Wang; Nan Lu; Yijing Liu; Wenpei Fan; Fuwu Zhang; Gang Niu; Shuo Hu; Iqbal Unnisa Ali; Xiaoyuan Chen
Journal:  Adv Mater       Date:  2016-11-28       Impact factor: 30.849

5.  Simulation of the osmosis-based drug encapsulation in erythrocytes.

Authors:  Duobiao Ge; Lili Zou; Chengpan Li; Sen Liu; Shibo Li; Sijie Sun; Weiping Ding
Journal:  Eur Biophys J       Date:  2017-09-20       Impact factor: 1.733

6.  DNA aptamer-mediated cell targeting.

Authors:  Xiangling Xiong; Haipeng Liu; Zilong Zhao; Meghan B Altman; Dalia Lopez-Colon; Chaoyong James Yang; Lung-Ji Chang; Chen Liu; Weihong Tan
Journal:  Angew Chem Int Ed Engl       Date:  2012-12-11       Impact factor: 15.336

7.  In vitro and in vivo degradation of Abeta peptide by peptidases coupled to erythrocytes.

Authors:  Yinxing Liu; Hanjun Guan; Tina L Beckett; Maria Aparecida Juliano; Luiz Juliano; Eun Suk Song; K Martin Chow; M Paul Murphy; Louis B Hersh
Journal:  Peptides       Date:  2007-09-29       Impact factor: 3.750

8.  Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.

Authors:  Juan-Carlos Murciano; Abd Al-Roof Higazi; Douglas B Cines; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2009-07-16       Impact factor: 9.776

9.  L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL).

Authors:  Young Min Kwon; Hee Sun Chung; Cheol Moon; James Yockman; Yoon Jeong Park; Scott D Gitlin; Allan E David; Victor C Yang
Journal:  J Control Release       Date:  2009-07-03       Impact factor: 9.776

10.  Drug-loaded sickle cells programmed ex vivo for delayed hemolysis target hypoxic tumor microvessels and augment tumor drug delivery.

Authors:  Se-woon Choe; David S Terman; Angela E Rivers; Jose Rivera; Richard Lottenberg; Brian S Sorg
Journal:  J Control Release       Date:  2013-07-18       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.